Fitness and infectivity of drug-resistant and cross-resistant HBV mutants: Why and how is it studied?

Antiviral Therapy

Volumn 15, Issue 3 PART B, 2010, Pages 521-527

  Durantel, David ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS DNA; VIRUS RNA;

ANTIVIRAL RESISTANCE; DRUG MONITORING; ENVIRONMENTAL FACTOR; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; VIRAL GENETICS; VIRION; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEPATITIS B; MEDICAL RESEARCH; MOUSE; MUTATION; PAN TROGLODYTES; PATHOGENICITY; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MICE; MUTATION; PAN TROGLODYTES; VIRUS REPLICATION;

EID: 77953423809     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1551     Document Type: Review

References (47)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
2. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 Suppl 1:S2-S19.
3. Zoulim F, Durantel D, Deny P. Management and prevention of drug resistance in chronic hepatitis B. Liver Int 2009; 29 Suppl 1:108-115.
4. Seeger C, Zoulim F, Mason WS. Hepadnaviruses. In Howley P, Knipe D (Editors). Fields Virology. Philadelphia: Lippincott 2007 pp. 2977-3029.
5. Litwin S, Toll E, Jilbert AR, Mason WS. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol 2005; 34 Suppl 1:S96-S107. (Pubitemid 43197756)
6. Zhang YY, Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000; 74:5257-5265. (Pubitemid 30313867)
7. Villet S, Billioud G, Pichoud C, et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009; 136:168-176.
8. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48:88-98. (Pubitemid 351975534)
9. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41:1391-1398. (Pubitemid 40770292)
10. Durantel D, Carrouee-Durantel S, Werle-Lapostolle B, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004; 40:855-864. (Pubitemid 39288118)
11. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-5444.
12. Delaney WE, Isom HC. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 1998; 28:1134-1146. (Pubitemid 28450278)
13. Durantel D, Brunelle MN, Gros E, et al. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 2005; 34 Suppl 1:S34-S43. (Pubitemid 43204242)
14. Lucifora J, Durantel D, Belloni L, et al. Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. J Gen Virol 2008; 89:1819-1828.
15. Ren S, Nassal M. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. J Virol 2001; 75:1104-1116. (Pubitemid 32094669)
16. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine. Hepatology 1998; 27:1670-1677. (Pubitemid 28264693)
17. Seigneres B, Pichoud C, Ahmed SS, Hantz O, Trepo C, Zoulim F. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis 2000; 181:1221-1233. (Pubitemid 30252525)
18. Yang H, Westland C, Xiong S, Delaney WE. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res 2004; 61:27-36. (Pubitemid 37506091)
19. Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006; 20:2229-2231. (Pubitemid 44684715)
20. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39:1085-1089. (Pubitemid 37523785)
21. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46:531-538. (Pubitemid 46201724)
22. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48:747-755.
23. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131:1253-1261. (Pubitemid 44515103)
24. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36:710-722.
25. Fu L, Cheng YC. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob Agents Chemother 2000; 44:3402-3407.
26. Qi X, Xiong S, Yang H, Miller M. Delaney WE 4th. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12:355-362.
27. Sun D, Nassal M. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol 2006; 45:636-645.
28. Yang H, Qi X, Sabogal A, Miller M, Xiong S. Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10:625-633.
29. Pawlotsky JM. The concept of hepatitis B virus mutant escape. J Clin Virol 2005; 34 Suppl 1:S125-S129.
30. Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008; 13:439-447.
31. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293:305-313.
32. Sureau C. The role of the HBV envelope proteins in the HDV replication cycle. Curr Top Microbiol Immunol 2006; 307:113-131.
33. Blanchet M, Sureau C. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity. J Virol 2006; 80:11935-11945.
34. Jaoude GA, Sureau C. Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus. J Virol 2005; 79:10460-10466.
35. Abou-Jaoude G, Sureau C. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol 2007; 81:13057-13066.
36. Salisse J, Sureau C. A function essential to viral entry underlies the hepatitis B virus 'a' determinant. J Virol 2009; 83:9321-9328.
37. Gripon P, Diot C, Theze N, et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 1988; 62:4136-4143.
38. Walter E, Keist R, Niederost B, Pult I, Blum HE. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 1996; 24:1-5.
39. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99:15655-15660.
40. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16:131-133.
41. Kamili S, Sozzi V, Thompson G, et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009; 49:1483-1491.
42. Kremsdorf D, Brezillon N. New animal models for hepatitis C viral infection and pathogenesis studies. World J Gastroenterol 2007; 13:2427-2435.
43. Meuleman P, Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res 2008; 80:231-238.
44. Sugiyama M, Tanaka Y, Kurbanov F, et al. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 2009; 136:652-662.
45. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26:335-341.
46. Dandri M, Burda MR, Zuckerman DM, et al. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol 2005; 42:54-60.
47. Tsuge M, Hiraga N, Takaishi H, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005; 42:1046-1054.